KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection

KSHV 亚单位候选疫苗可引发针对 KSHV 感染的有效体液免疫反应

基本信息

项目摘要

PROJECT SUMMARY Kaposi sarcoma-associated herpesvirus (KSHV) has been classified as a direct carcinogen by the International Agency for Research on Cancer because of its ability to cause Kaposi sarcoma (KS) and two rare types of B-cell lymphoma. KS frequently occurs among iatrogenic or HIV/AIDS-induced immunosuppressed individuals. To date, there is no licensed KSHV vaccine that can prevent primary infection and subsequent malignancies. Our objective in this application is to optimize the inclusion of key KSHV glycoproteins (gps), which are involved in epithelial, endothelial, fibroblast and B-cell entry, into multivalent subunit vaccine candidates that can stimulate neutralizing antibody (nAb) immune responses to prevent or limit KSHV infection and KSHV+ cancers in vivo. This application builds on my recently completed NCI K01 CA184388-05 research on KSHV entry mechanisms and vaccine development. Recently, we showed that in vitro, the KSHV glycoprotein gH is essential for viral infection of epithelial, endothelial, and fibroblasts cells, but not B cells. Notably, we and other have also shown that both monoclonal and polyclonal Abs to KSHV glycoproteins K8.1, gB, and gH/gL can neutralize KSHV infection of diverse permissive human cells in vitro. Building on this success, we have generated quadrivalent virus-like particles (KSHV-LPs) incorporating the four glycoproteins critical for viral entry (K8.1, gB and gH/gL). In this application we will use wild-type and humanized mice and common marmoset (Callithrix jacchus) models to test the hypothesis that purified KSHV-LPs delivered directly or through immunization with a modified vaccinia Ankara vector (MVA-KSHV-LPs) will elicit robust protective nAb responses to KSHV infection and its associated malignancies. The premise of our proposal is built on strong evidence that 1) infection with KSHV does not occur during early childhood, as is typical for other herpesviruses, opening a window of opportunity for vaccination and 2) Abs against the KSHV glycoproteins K8.1, gB, and gH/gL can neutralize KSHV infection. Furthermore, the permissiveness of humanized mice and marmosets to KSHV infection offers an ideal platform to test candidate vaccines. Thus, a polyvalent vaccine that induces prophylactic neutralizing Abs responses will not only be an invaluable candidate vaccine in preventing KSHV infection, but also of utmost importance in preventing KSHV-associated diseases. We will provide evidence for the safety of our candidate KSHV vaccine based on three pre-clinical animal models as prerequisite data for an IND application for a phase I clinical trial. In the long term, the success of our approach will introduce a new vaccine to the market with a potential for reducing global incidence of KSHV+ malignancies (>44,000 cases/year), and the possibility of limiting KSHV infection and associated malignancies in developing countries or eradicating them from developed countries where KSHV seroprevalence is <10%.
项目摘要 卡波西肉瘤相关疱疹病毒(KSHV)已被国际分类为直接致癌物。 癌症研究机构,因为它的能力,导致卡波西肉瘤(KS)和两种罕见的类型, B细胞淋巴瘤KS常发生在医源性或HIV/AIDS诱导的免疫抑制个体中。 到目前为止,还没有获得许可的KSHV疫苗可以预防原发性感染和随后的恶性肿瘤。 我们在本申请中的目标是优化关键KSHV糖蛋白(gps)的包含, 参与上皮、内皮、成纤维细胞和B细胞进入的多价亚单位疫苗候选物, 可以刺激中和抗体(nAb)免疫应答,以预防或限制KSHV感染和KSHV+ 体内的癌症此应用程序基于我最近完成的NCI K 01 CA 184388 -05对KSHV的研究 进入机制和疫苗开发。最近,我们发现在体外,KSHV糖蛋白gH是 对于上皮细胞、内皮细胞和成纤维细胞的病毒感染是必需的,但对B细胞不是必需的。特别是,我们和其他 还表明,抗KSHV糖蛋白K8.1、gB和gH/gL的单克隆和多克隆抗体均能 在体外中和多种允许的人细胞的KSHV感染。在这一成功的基础上,我们 产生的四价病毒样颗粒(KSHV-LPs),其中包含病毒关键的四种糖蛋白, 条目(K8.1、gB和gH/gL)。在本申请中,我们将使用野生型和人源化小鼠以及常见的 绒猴(Callithrix jacchus)模型来检验纯化的KSHV-LP直接或间接递送的假设。 通过用修饰的安卡拉牛痘载体(MVA-KSHV-LPs)免疫将引发强保护性nAb 对KSHV感染及其相关恶性肿瘤的反应。我们提案的前提是 有证据表明:1)KSHV感染不会发生在儿童早期,这是典型的其他 疱疹病毒,为疫苗接种打开了机会之窗,2)针对KSHV糖蛋白的抗体 K8.1、gB和gH/gL能中和KSHV感染。此外,人源化小鼠和 绒猴对KSHV感染的耐受性为测试候选疫苗提供了一个理想的平台。因此,多价疫苗 诱导预防性中和抗体反应的疫苗不仅是一种宝贵的候选疫苗, 预防KSHV感染,而且在预防KSHV相关疾病方面也至关重要。我们将 基于三种临床前动物模型,为我们的候选KSHV疫苗的安全性提供证据, I期临床试验IND申请的先决条件数据。从长远来看,我们方法的成功 将向市场推出一种新疫苗,有可能降低KSHV+的全球发病率 恶性肿瘤(> 44,000例/年),以及限制KSHV感染和相关恶性肿瘤的可能性 在发展中国家或在KSHV血清阳性率<10%的发达国家根除它们。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Javier Gordon Ogembo其他文献

Correction: HPV genotyping by L1 amplicon sequencing of archived invasive cervical cancer samples: a pilot study
  • DOI:
    10.1186/s13027-024-00589-0
  • 发表时间:
    2024-06-19
  • 期刊:
  • 影响因子:
    2.800
  • 作者:
    Charles D. Warden;Preetam Cholli;Hanjun Qin;Chao Guo;Yafan Wang;Chetan Kancharla;Angelique M. Russell;Sylvana Salvatierra;Lorraine Z. Mutsvunguma;Kerin K. Higa;Xiwei Wu;Sharon Wilczynski;Raju Pillai;Javier Gordon Ogembo
  • 通讯作者:
    Javier Gordon Ogembo

Javier Gordon Ogembo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Javier Gordon Ogembo', 18)}}的其他基金

Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
  • 批准号:
    10623087
  • 财政年份:
    2021
  • 资助金额:
    $ 85.8万
  • 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
  • 批准号:
    10318876
  • 财政年份:
    2021
  • 资助金额:
    $ 85.8万
  • 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
  • 批准号:
    10474478
  • 财政年份:
    2021
  • 资助金额:
    $ 85.8万
  • 项目类别:
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection
KSHV 亚单位候选疫苗可引发针对 KSHV 感染的有效体液免疫反应
  • 批准号:
    10559659
  • 财政年份:
    2021
  • 资助金额:
    $ 85.8万
  • 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
  • 批准号:
    10737872
  • 财政年份:
    2021
  • 资助金额:
    $ 85.8万
  • 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
  • 批准号:
    10627167
  • 财政年份:
    2021
  • 资助金额:
    $ 85.8万
  • 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
  • 批准号:
    10599690
  • 财政年份:
    2021
  • 资助金额:
    $ 85.8万
  • 项目类别:
A multivalent prophylactic and therapeutic vaccine against EBV infection and EBV-associated malignancies
针对 EBV 感染和 EBV 相关恶性肿瘤的多价预防性和治疗性疫苗
  • 批准号:
    10247243
  • 财政年份:
    2020
  • 资助金额:
    $ 85.8万
  • 项目类别:
Characterization of Epstein-Barr virus monoclonal antibodies as tools for diagnosing and prevention of EBV infection in transplant settings
EB 病毒单克隆抗体作为移植环境中诊断和预防 EBV 感染工具的表征
  • 批准号:
    9797160
  • 财政年份:
    2018
  • 资助金额:
    $ 85.8万
  • 项目类别:
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
一种预防 EBV 感染和 EBV 相关恶性肿瘤的新型 VLP 疫苗
  • 批准号:
    9302981
  • 财政年份:
    2017
  • 资助金额:
    $ 85.8万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 85.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了